Lynparza will be the first PARP inhibitor cleared for maintenance treatment to extend response to first-line chemo, but in BRCA mutant patients – while Tesaro/GSK should have Phase III results for Zejula monotherapy in all-comers in 2019.
AstraZeneca PLC/Merck & Co. Inc.'s Lynparza is breaking new ground in ovarian cancer with the first approval of a PARP inhibitor as first-line maintenance therapy in BRCA-mutated ovarian cancer.
After a speedy review, the US FDA approved Lynparza (olaparib) Dec. 19 as a monotherapy in BRCA+ patients in partial...
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
